Jan 27 (Reuters) - Alexandria Real Estate Equities ARE.N posted a rise in its fourth-quarter funds from operations on Monday, as the real estate investment trust benefited from steady leasing demand from biotech clients and technology-focused firms.
The Pasadena, California-based company operates and develops life science laboratories, offices and technology campuses across North America.
Its clients include Bristol Myers Squibb BMY.N, Moderna MRNA.O and Eli Lilly LLY.N, as well as agricultural tech companies and research institutions.
Occupancy of Alexandria's operating properties held steady at 94.6% as of Dec. 31, compared with the year earlier.
FFO, a key performance measure for REITs, came in at $411.8 million, or $2.39 per share, for the quarter, compared with $389.8 million, or $2.28 per share, a year ago.
Its total revenue for the quarter rose 4.2% to $788.9 million.
(Reporting by Aatreyee Dasgupta and Nathan Gomes in Bengaluru; Editing by Shilpi Majumdar)
((Aatreyee.Dasgupta@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。